Empagliflozin to prevent post-operative atrial fibrillation in patients undergoing coronary artery bypass graft surgery: Rationale and design of the EMPOAF trial.
CABG
SGLT2 inhibitors
atrial fibrillation
cardiac surgery
empagliflozin
post‐operative AF
Journal
Pacing and clinical electrophysiology : PACE
ISSN: 1540-8159
Titre abrégé: Pacing Clin Electrophysiol
Pays: United States
ID NLM: 7803944
Informations de publication
Date de publication:
30 Jun 2024
30 Jun 2024
Historique:
revised:
31
05
2024
received:
07
02
2024
accepted:
18
06
2024
medline:
1
7
2024
pubmed:
1
7
2024
entrez:
1
7
2024
Statut:
aheadofprint
Résumé
Postoperative atrial fibrillation (POAF) is one of the most common types of acute AF and can complicate the treatment course of approximately one third of patients undergoing cardiac surgery. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are among the newest antidiabetic drugs which can be therapeutic options for preventing POAF by different mechanisms. Empagliflozin to Prevent POAF (EMPOAF) is an interventional, investigator-initiated, double-blind, placebo-controlled, multicenter, randomized controlled trial which will be conducted in two referral teaching cardiology hospitals in Tehran. Four-hundred ninety-two adult patients who are scheduled for elective isolated coronary artery bypass graft (CABG) surgery will be randomly assigned to one of the groups of intervention (empagliflozin 10 mg daily) or placebo starting at least 3 days before surgery until discharge. Key exclusion criteria are a history of diabetes mellitus, AF, ketoacidosis, or recurrent urinary tract infections along with severe renal or hepatic impairment, unstable hemodynamics, and patients receiving SGLT2 inhibitors for another indication. The primary outcome will be the incidence of POAF. Key secondary endpoints will be the composite rate of life-threatening arrhythmias, postoperative acute kidney injury, hospitalization length, in-hospital mortality, stroke, and systemic embolization. Key safety endpoints will be the rate of life-threatening and/or genitourinary tract infections, hypoglycemia, and ketoacidosis. EMPOAF will prospectively evaluate whether empagliflozin 10 mg daily can reduce the rate of POAF in patients undergoing elective CABG. Enrolment into this study has started by November 2023 and is expected to be ended before the end of 2025.
Sections du résumé
BACKGROUND
BACKGROUND
Postoperative atrial fibrillation (POAF) is one of the most common types of acute AF and can complicate the treatment course of approximately one third of patients undergoing cardiac surgery. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are among the newest antidiabetic drugs which can be therapeutic options for preventing POAF by different mechanisms.
METHODS
METHODS
Empagliflozin to Prevent POAF (EMPOAF) is an interventional, investigator-initiated, double-blind, placebo-controlled, multicenter, randomized controlled trial which will be conducted in two referral teaching cardiology hospitals in Tehran. Four-hundred ninety-two adult patients who are scheduled for elective isolated coronary artery bypass graft (CABG) surgery will be randomly assigned to one of the groups of intervention (empagliflozin 10 mg daily) or placebo starting at least 3 days before surgery until discharge. Key exclusion criteria are a history of diabetes mellitus, AF, ketoacidosis, or recurrent urinary tract infections along with severe renal or hepatic impairment, unstable hemodynamics, and patients receiving SGLT2 inhibitors for another indication. The primary outcome will be the incidence of POAF. Key secondary endpoints will be the composite rate of life-threatening arrhythmias, postoperative acute kidney injury, hospitalization length, in-hospital mortality, stroke, and systemic embolization. Key safety endpoints will be the rate of life-threatening and/or genitourinary tract infections, hypoglycemia, and ketoacidosis.
CONCLUSIONS
CONCLUSIONS
EMPOAF will prospectively evaluate whether empagliflozin 10 mg daily can reduce the rate of POAF in patients undergoing elective CABG. Enrolment into this study has started by November 2023 and is expected to be ended before the end of 2025.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Research Centers of Rajaie Cardiovascular Institute and Tehran Heart Center
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Lubitz SA, Yin X, Rienstra M, et al. Long‐term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study. Circulation. 2015;131:1648‐1655.
Chyou JY, Barkoudah E, Dukes JW, et al. Atrial fibrillation occurring during acute hospitalization: a scientific statement from the American Heart Association. Circulation. 2023;147:e676‐e698.
Dobrev D, Aguilar M, Heijman J, Guichard JB, Nattel S. Postoperative atrial fibrillation: mechanisms, manifestations and management. Nat Rev Cardiol. 2019;16:417‐436.
Melduni RM, Schaff HV, Bailey KR, et al. Implications of new‐onset atrial fibrillation after cardiac surgery on long‐term prognosis: a community‐based study. Am Heart J. 2015;170:659‐668.
Perrier S, Meyer N, Hoang Minh T, et al. Predictors of atrial fibrillation after coronary artery bypass grafting: a Bayesian analysis. Ann Thorac Surg. 2017;103:92‐97.
Hravnak M, Hoffman LA, Saul MI, Zullo TG, Whitman GR. Resource utilization related to atrial fibrillation after coronary artery bypass grafting. Am J Crit Care. 2002;11:228‐238.
Lowres N, Mulcahy G, Jin K, Gallagher R, Neubeck L, Freedman B. Incidence of postoperative atrial fibrillation recurrence in patients discharged in sinus rhythm after cardiac surgery: a systematic review and meta‐analysis. Interact Cardiovasc Thorac Surg. 2018;26:504‐511.
Albini A, Malavasi VL, Vitolo M, et al. Long‐term outcomes of postoperative atrial fibrillation following non cardiac surgery: a systematic review and metanalysis. Eur J Intern Med. 2021;85:27‐33.
Benedetto U, Gaudino MF, Dimagli A, et al. Postoperative Atrial Fibrillation and Long‐Term Risk of Stroke After Isolated Coronary Artery Bypass Graft Surgery. Circulation. 2020;142:1320‐1329.
Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114:1453‐1468.
Rezaei Y, Peighambari MM, Naghshbandi S, et al. Postoperative atrial fibrillation following cardiac surgery: from pathogenesis to potential therapies. Am J Cardiovasc Drugs. 2020;20:19‐49.
Rezaei Y, Gholami‐Fesharaki M, Dehghani MR, Arya A, Haghjoo M, Arjmand N. Statin antiarrhythmic effect on atrial fibrillation in statin‐naive patients undergoing cardiac surgery: a meta‐analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2016;21:167‐176.
Banach M, Rysz J, Drozdz JA, et al. Risk factors of atrial fibrillation following coronary artery bypass grafting: a preliminary report. Circ J. 2006;70:438‐441.
Müller P, Hars C, Schiedat F, et al. Correlation between total atrial conduction time estimated via tissue Doppler imaging (PA‐TDI Interval), structural atrial remodeling and new‐onset of atrial fibrillation after cardiac surgery. J Cardiovasc Electrophysiol. 2013;24:626‐631.
Piña IL. SGLT2 inhibitors: the story continues to unfold. Eur Heart J. 2021;42:4902‐4904.
Kolesnik E, Scherr D, Rohrer U, et al. SGLT2 inhibitors and their antiarrhythmic properties. Int J Mol Sci. 2022;23:1678.
Shetty SS, Krumerman A. Putative protective effects of sodium‐glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off‐target actions: potential mechanisms and future directions. Cardiovasc Diabetol. 2022;21:119.
Nishinarita R, Niwano S, Niwano H, et al. Canagliflozin suppresses atrial remodeling in a canine atrial fibrillation model. J Am Heart Assoc. 2021;10:e017483.
Li D, Liu Y, Hidru TH, et al. Protective effects of sodium‐glucose transporter 2 inhibitors on atrial fibrillation and atrial flutter: a systematic review and meta‐ analysis of randomized placebo‐controlled trials. Front Endocrinol. 2021;12:619586.
Wang M, Zhang Y, Wang Z, Liu D, Mao S, Liang B. The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta‐analysis. J Thorac Dis. 2022;14:1620‐1637.
Li HL, Lip GYH, Feng Q, et al. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta‐analysis. Cardiovasc Diabetol. 2021;20:100.
Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of Dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE‐TIMI 58 trial. Circulation. 2020;141:1227‐1234.
Böhm M, Slawik J, Brueckmann M, et al. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial. Eur J Heart Fail. 2020;22:126‐135.
Li WJ, Chen XQ, Xu LL, Li YQ, Luo BH. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta‐analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020;19:130.
Virani SS, Newby LK, Arnold SV, et al. AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of cardiology joint committee on clinical practice guidelines. Circulation. 2023;148:e9‐e119.
Lawton JS, Tamis‐Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiologs. Circulation. 2022;145:e4‐e17.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117‐2128.
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413‐1424.
Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117‐127.
Heijman J, Voigt N, Nattel S, Dobrev D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014;114:1483‐1499.
Trum M, Riechel J, Lebek S, et al. Empagliflozin inhibits Na(+) /H(+) exchanger activity in human atrial cardiomyocytes. ESC Heart Fail. 2020;7:4429‐4437.
Yurista SR, Silljé HHW, Rienstra M, de Boer RA, Westenbrink BD. Sodium‐glucose co‐transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? Cardiovasc Diabetol. 2020;19:5.
Kalman JM, Munawar M, Howes LG, et al. Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann Thorac Surg. 1995;60:1709‐1715.
Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C‐reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96:3542‐3548.
Alexandre J, Saloux E, Chequel M, et al. Preoperative plasma aldosterone and the risk of atrial fibrillation after coronary artery bypass surgery: a prospective cohort study. J Hypertens. 2016;34:2449‐2457.
Theofilis P, Sagris M, Oikonomou E, et al. The impact of SGLT2 inhibitors on inflammation: a systematic review and meta‐analysis of studies in rodents. Int Immunopharmacol. 2022;111:109080.
Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA‐HEART CardioLink‐6 randomized clinical trial. Circulation. 2019;140:1693‐1702.
Arsenault KA, Yusuf AM, Crystal E, et al. Interventions for preventing post‐operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2013;2013:Cd003611.
Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of post‐operative atrial fibrillation and its complications after cardiac surgery: a meta‐analysis. Eur Heart J. 2006;27:2846‐2857.
Lennerz C, Barman M, Tantawy M, Sopher M, Whittaker P. Colchicine for primary prevention of atrial fibrillation after open‐heart surgery: systematic review and meta‐analysis. Int J Cardiol. 2017;249:127‐137.
Wijeysundera DN, Beattie WS, Rao V, Karski J. Calcium antagonists reduce cardiovascular complications after cardiac surgery: a meta‐analysis. J Am Coll Cardiol. 2003;41:1496‐1505.
Zhen‐Han L, Rui S, Dan C, Xiao‐Li Z, Qing‐Chen W, Bo F. Perioperative statin administration with decreased risk of postoperative atrial fibrillation, but not acute kidney injury or myocardial infarction: a meta‐analysis. Sci Rep. 2017;7:10091.
Zhang B, Zhen Y, Tao A, Bao Z, Zhang G. Polyunsaturated fatty acids for the prevention of atrial fibrillation after cardiac surgery: an updated meta‐analysis of randomized controlled trials. J Cardiol. 2014;63:53‐59.
Whitlock RP, Devereaux PJ, Teoh KH, et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double‐blind, placebo‐controlled trial. Lancet. 2015;386:1243‐1253.